Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
HRTX
#3001
Heron Therapeutics, Inc.
1.1
9
-0.83%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.83%
Monatliche Änderung
-14.39%
6 month change
-11.85%
Jahresänderung
-39.90%
Vorheriger Schlusskurs
1.2
0
Open
1.1
9
Bid
Ask
Low
1.1
9
High
1.1
9
Volumen
58
Märkte
Aktien
Gesundheitswesen
HRTX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
91.4 M
102.14 M
119.26 M
150.33 M
152.33 M
188.54 M
—
Valuation ratios
Enterprise value
1.83 B
842 M
274.44 M
255.44 M
207.26 M
217.5 M
1.03 B
Price to earnings ratio
—
—
-1.46
-2.36
-17
-10.83
-165
Price to sales ratio
—
—
2.46
2.05
1.62
—
—
Price to cash flow ratio
—
—
1.8
4.44
10.35
7.85
43.64
Price to book ratio
—
—
19.49
7.68
6.93
16.32
23.56
Enterprise value to EBITDA ratio
279.79
239.48
15.14
16.78
3.78
—
—
Profitability ratios
Return on assets %
0.64
0.72
0.73
0.5
0.06
0.08
0.08
Return on equity %
0.96
2.84
13.41
3.25
0.4
1.41
1.21
Return on invested capital %
1 091.33
872.93
674.56
465.61
48.29
8.33
—
Gross margin %
59.15
46.7
49.04
48.75
73.21
73.31
293.19
Operating margin %
257.52
252.27
162.21
87.07
7.99
1.64
7.58
EBITDA margin %
7.38
4.07
16.83
11.98
37.96
46.87
148.46
Net margin %
256.52
255.58
169.03
87.02
9.41
13.04
52.44
Liquidity ratios
Quick ratio
2.66
2.9
1.83
1.84
1.7
1.51
5.58
Current ratio
3.07
3.58
2.49
2.37
2.29
2.48
8.25
Inventory turnover
1.08
1.02
1.07
1.35
0.81
0.57
0.61
Asset turnover
0.2
0.26
0.39
0.54
0.63
0.63
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.49
0.59
0.67
0.64
0.13
1.54
Long term debt to total equity ratio
—
1.92
11
4.4
4.45
2.28
15.2
Per share metrics
Operating cash flow per share
—
—
1.35
0.43
0.15
0.17
0.16
EBIT per share
—
—
0.14
0.09
0.34
0.42
0.31
EBITDA per share
—
—
0.17
0.11
0.36
0.44
0.33
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
0.78
0.58
0.39
0.28
1.13
Net current asset value per share
—
—
1.89
1.37
1.37
1.43
5.23
Tangible book value per share
—
—
0.12
0.25
0.22
0.08
0.44
Working capital per share
—
—
1.13
0.79
0.77
0.85
1.99
Book value per share
—
—
0.12
0.25
0.22
0.08
0.44
Nachrichten
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeuti: EPS verfehlt Schätzungen - Umsatz besser als erwartet
Heron Therapeuti earnings missed, revenue topped estimates
Heron Q4 2025: Wachstumsschub in der Akutversorgung treibt ZYNRELEF-Umsatz um 48 %
Heron Q4 2025 slides: acute care surge drives 48% ZYNRELEF growth
Heron Therapeutics: Aktie legt nach starken Q4-Umsätzen kräftig zu
Heron Therapeutics stock soars after strong Q4 revenue growth
Heron Therapeutics: APONVIE in neue Richtlinien gegen postoperative Übelkeit aufgenommen
Heron’s APONVIE featured in new postoperative nausea guidelines
Jefferies senkt Kursziel für Heron Therapeutics wegen schwächelndem Onkologie-Geschäft
Jefferies lowers Heron Therapeutics stock price target on oncology franchise decline
Heron Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:HRTX) 2025-11-04